Literature DB >> 504040

Tienilic acid: pharmacokinetics, salicylate interaction and creatinine secretion studies.

J W Dubb, R M Stote, A R Maass, B V Hwang, R G Familiar, F Alexander.   

Abstract

Tienilic acid is a diuretic-uricosuric compound whose natriuretic site of action is in the cortical diluting segment of the distal nephron. Oral doses of 250 mg given to normal human volunteers provided peak blood levels of 10--11 micrograms/ml at 3--4 hours after administration. Approximately 40% of the dose was recovered in 24 hours, 30% as the parent compound and 10% as the alcohol and diacid metabolites. A 650 mg dose of acetylsalicylic acid significantly decreased the uricosuric effect of tienilic acid by inhibiting uric acid secretion. Urine pH fell significantly with tienilic acid administration. Tienilic acid inhibited salicylate excretion by either competition for tubular secretion or by increasing passive, pH dependent reabsorption. In normal subjects given a creatinine load, tienilic acid did not inhibit creatinine secretion.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 504040

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  4 in total

1.  Risk assessment of mechanism-based inactivation in drug-drug interactions.

Authors:  Yasushi Fujioka; Kent L Kunze; Nina Isoherranen
Journal:  Drug Metab Dispos       Date:  2012-06-08       Impact factor: 3.922

2.  Immune mechanisms in tienilic acid associated hepatotoxicity.

Authors:  J Neuberger; R Williams
Journal:  Gut       Date:  1989-04       Impact factor: 23.059

Review 3.  Diuretics. Clinical pharmacology and therapeutic use (Part II).

Authors:  A Lant
Journal:  Drugs       Date:  1985-02       Impact factor: 9.546

4.  Pharmacokinetic and pharmacodynamic studies of tienilic acid in healthy volunteers.

Authors:  A L Kerremans; F W Gribnau; Y Tan; C A van Ginneken
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.